Compare Medpace Holdings Inc (MEDP) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs PepsiCo, Inc. — how do they compare? Medpace Holdings Inc trades at $598 (market cap $16.90B), while PepsiCo, Inc. trades at $138.59 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 11.2× Medpace Holdings Inc's market cap, and PepsiCo, Inc. pays a 4.28% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PEP | |
|---|---|---|
Market Cap | $16.90B | $188.91B |
Sector | Technology | Consumer Staples |
52-Week High | $620.59 | $170.44 |
52-Week Low | $393.42 | $134.95 |
Enterprise Value | $16.52B | $231.41B |
Dividend Yield | — | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
PepsiCo (PEP) trades at $138.41, up 0.52% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025, with a net income margin of 10.78% and a P/E ratio of 18.14. Recent earnings have consistently beaten expectations, and analysts project a consensus price target of $158.79. News highlights include price cuts on snacks to address consumer pushback and the cessation of a festival sponsorship.
The outlook for PEP is cautiously optimistic, supported by strong profitability and dividend payments, but faces risks from competitive pressures and price sensitivity. Upside potential exists if North American performance improves as anticipated in upcoming earnings. Investor sentiment is mixed, with a majority of analysts recommending Hold, reflecting balanced growth prospects against near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
